Back to results
US 7,252,976 B2Granted
Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
AssigneeBoard of Regents, The University of Texas System
InventorsEdward H. Lin, Xifeng Wu, Keping Xie
Life of this patent
Estimating the term…
Abstract
The present invention involves the use of quantitative RT-PCR to identify AC133 as a marker. AC133 is prevalent on endothelial progenitor cells (EPCs), which are important cells in angiogenesis. Therefore, the invention is applied to ascertain the quantity of EPCs in a subject, and to diagnose and monitor angiogenesis, for example, in injured tissues and in cancer development and progression.
Claims9
A method for diagnosing colorectal cancer in a human subject having colorectal cancer or at risk of developing colorectal cancer comprising:
- (a) obtaining a peripheral blood sample of said subject;
- (b) obtaining RNA transcripts from peripheral blood mononuclear cells of said sample;
- (c) performing quantitative polymerase chain reaction on said RNA using primers that amplify an AC133 nucleic acid segment;
- and
- (d) comparing the amount of AC133 amplification product with the amount of amplification product in a non-cancer, control sample of peripheral blood mononuclear cells,
- wherein an increase in the amount of AC133 amplification product in peripheral blood mononuclear cells of said subject, as compared to the amount of AC133 amplification product in the non-cancer, control sample of peripheral blood mononuclear cells, indicates that said subject has colorectal cancer.
3 more elements
Dependencies are inferred from the claim text.